Contact
Please use this form to send email to PR contact of this press release:
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
TO:
Please use this form to send email to PR contact of this press release:
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
TO: